Tumour protein p53 (TP53) is a tumour suppressor gene that is frequently mutated in cancers. Traditional TP53 detection methods, such as polymerase chain reactions, are time-consuming and demand skilled laboratory personnel. As an alternative, in the current study, we have demonstrated a high resistivity silicon (HR-Si) based conductometric biosensor designed for the rapid and specific identification of TP53 point mutations directly at the point-of-need. This biosensor accurately detected R248Q and R248W point mutant single strand DNA (ssDNA) as models, in real-time. Both R248Q and R248W mutant ssDNA exhibited a limit of detection (LOD) of 0.5 ng/mL in human plasma. The selectivity studies revealed that both R248Q and R248W mutant ssDNA can be detected 10 × lower molar content against their wild-type ssDNA. Validation of the sensor using clinical samples harbouring known TP53 mutations demonstrated a sensitivity of 100%, a specificity of 100%, and a LOD of 2.5 ng/mL. This precision biosensing platform at the point-of-need has the potential to revolutionise cancer diagnostics.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.bios.2025.117252 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Rapid and selective detection of TP53 mutations in cancer using a novel conductometric biosensor.
Biosens Bioelectron
May 2025
Institute for Biomedicine and Glycomics (IBG), Griffith University, Nathan, QLD 4111, Australia. Electronic address:
Tumour protein p53 (TP53) is a tumour suppressor gene that is frequently mutated in cancers. Traditional TP53 detection methods, such as polymerase chain reactions, are time-consuming and demand skilled laboratory personnel. As an alternative, in the current study, we have demonstrated a high resistivity silicon (HR-Si) based conductometric biosensor designed for the rapid and specific identification of TP53 point mutations directly at the point-of-need.
View Article and Find Full Text PDFMultidimensional quantitative phenotypic and molecular analysis reveals neomorphic behaviors of p53 missense mutants.
NPJ Breast Cancer
September 2023
The Biodesign Center for Personalized Diagnostics, Biodesign Institute, Arizona State University, Tempe, AZ, 85287, USA.
Mutations in the TP53 tumor suppressor gene occur in >80% of the triple-negative or basal-like breast cancer. To test whether neomorphic functions of specific TP53 missense mutations contribute to phenotypic heterogeneity, we characterized phenotypes of non-transformed MCF10A-derived cell lines expressing the ten most common missense mutant p53 proteins and observed a wide spectrum of phenotypic changes in cell survival, resistance to apoptosis and anoikis, cell migration, invasion and 3D mammosphere architecture. The p53 mutants R248W, R273C, R248Q, and Y220C are the most aggressive while G245S and Y234C are the least, which correlates with survival rates of basal-like breast cancer patients.
View Article and Find Full Text PDFGain-of-Function and Non-Gain-of-Function Mutations Are Associated With Differential Prognosis in Advanced Pancreatic Ductal Adenocarcinoma.
JCO Precis Oncol
May 2023
Division of Research, Kaiser Permanente, Oakland, CA.
Purpose: To examine the impact of gain-of-function (GOF) and non-GOF mutations on prognosis of advanced pancreatic ductal adenocarcinoma (PDAC) among patients with , , and comutations.
Methods: This cohort included patients with locally advanced, recurrent, and de novo metastatic PDAC with next-generation sequencing performed from November 2017 to May 2022. We defined R175H, R248W, R248Q, R249S, R273H, R273L, and R282W as GOF and all other p53 mutations (mutp53) as non-GOF.
Assessment of Thermal Stability of Mutant p53 Proteins via Differential Scanning Fluorimetry.
Life (Basel)
December 2022
Institute of Fundamental Medicine and Biology, Kazan Federal University, 420008 Kazan, Russia.
The p53 protein is a transcription factor that preserves the integrity of the genome. The gene has inactivating mutations in about 50% of all human cancers. Some missense mutations lead to decreased thermal stability in the p53 protein, its unfolding and aggregation under physiological conditions.
View Article and Find Full Text PDFTP-0903 Is Active in Preclinical Models of Acute Myeloid Leukemia with Mutation/Deletion.
Cancers (Basel)
December 2022
Division of Pharmaceutics and Pharmacology, The Ohio State University, Columbus, OH 43212, USA.
Acute myeloid leukemia (AML) with mutations in the tumor suppressor gene TP53 confers a dismal prognosis with 3-year overall survival of <5%. While inhibition of kinases involved in cell cycle regulation induces synthetic lethality in a variety of TP53 mutant cancers, this strategy has not been evaluated in mutant TP53 AML. Previously, we demonstrated that TP-0903 is a novel multikinase inhibitor with low nM activity against AURKA/B, Chk1/2, and other cell cycle regulators.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!